Primary tumour response on breast MRI as a predictor of axillary pathologic response in breast cancer patients treated with neoadjuvant chemotherapy - Scorecard - MDSpire
Advertisement
Primary tumour response on breast MRI as a predictor of axillary pathologic response in breast cancer patients treated with neoadjuvant chemotherapy
Clinical Scorecard: Assessment of Primary Tumour Changes on Breast MRI as an Indicator of Axillary Pathological Response in Patients Undergoing Neoadjuvant Chemotherapy for Breast Cancer
At a Glance
Category
Detail
Condition
Breast cancer undergoing neoadjuvant chemotherapy
Key Mechanisms
Breast MRI assessment of primary tumour response (radiologic complete response) to predict axillary pathological response
Target Population
Female patients with invasive breast cancer (cT1-4N0-3) treated with neoadjuvant chemotherapy
Care Setting
Tertiary care center with breast MRI and surgical oncology services
Key Highlights
Breast radiologic complete response (rCR) on MRI is defined as absence of residual malignancy or enhancement post-NACT.
Pathologic complete response (ypT0 and/or ypN0) after NACT correlates with improved long-term survival.
Breast MRI has limitations in axillary lymph node visualization, complicating direct axillary response assessment.
Guideline-Based Recommendations
Diagnosis
Use breast MRI pre- and post-NACT to assess primary tumour response, applying BI-RADS lexicon criteria for rCR.
Determine clinical nodal status (cN) by axillary ultrasound and biopsy prior to NACT.
Assess ER and HER2 status from baseline core biopsy to classify tumour subtype.
Management
Consider breast MRI findings of rCR to potentially predict axillary pathologic response and guide axillary treatment de-escalation.
Use pathological evaluation of breast and axillary tissue post-NACT as reference standard for treatment response.
Monitoring & Follow-up
Monitor tumour response during NACT with breast MRI using standardized imaging protocols.
Evaluate axillary lymph node response with ultrasound and biopsy as MRI coverage may be limited.
Risks
Incomplete visualization of axillary lymph nodes on breast MRI may lead to underestimation of residual disease.
Pathologic response can only be definitively assessed after surgery, limiting preoperative decision-making.
Patient & Prescribing Data
Female invasive breast cancer patients undergoing neoadjuvant chemotherapy with baseline and post-treatment breast MRI
Breast MRI radiologic complete response correlates with higher likelihood of axillary pathologic complete response, especially in clinically node-negative and certain receptor subtype subgroups.
Clinical Best Practices
Perform baseline and post-NACT breast MRI using standardized protocols and dedicated breast coils in prone position.
Classify breast MRI response using BI-RADS criteria, including possible or near rCR as rCR.
Integrate clinical nodal status and receptor subtype information to interpret MRI findings and predict axillary response.
Use multidisciplinary approach combining imaging, pathology, and clinical data to guide axillary surgery decisions.
by Florien J. G. van Amstel, Rik G. M. van Mierlo, Patty J. Nelemans, Sanne M. E. Engelen, Janneke Houwers, Loes F. S. Kooreman, Vivianne C. G. Tjan-Heijnen, Sabine Siesling, Marjolein L. Smidt, Thiemo J. A. van Nijnatten
